| Rolf A. Classon |
Chairman of our Board |
- Served as interim President and Chief Executive Officer Of Xanodyne from April 2007 to July 2007.
- Several positions with Bayer AG including Chairman of the Executive Committee of Bayer Healthcare
- Chairman of the board of directors of Hillenbrand Industries, Inc. and Auxilium Pharmaceuticals, Inc.
- Director of Millipore Corporation, Enzon Pharmaceuticals, Inc., PharmaNet Development Group, Inc. and Eurand N.V.
- Degree in chemical engineering from the Gothenburg School of Engineering (Sweden) and a politices magister degree from the University of Gothenburg in Sweden
|
| Natasha Giordano |
President and CEO, Xanodyne Pharmaceuticals, Inc. |
- President Americas for Cegedim Dendrite
- Senior Vice President, Global Customer Business Unit for Dendrite International
- Vice President, Global Sales for Dendrite International
- Director, Strategic Alliances & Sales Integration for Parke-Davis/Pfizer
- Business Director, Northeast Customer Business Unit for Parke-Davis/Warner-Lambert
- BSRN - Wagner College
|
| Vaughn Kailian |
Director |
- Managing Director of MPM Capital
- Chairman of Elixir Pharmaceuticals Inc., Cerimon Pharmaceuticals Inc. and Veritas Inc.
- CEO of COR Therapeutics, Inc.
- U.S. and International general management positions at Marion Merrell Dow, Inc.
- BA, Tufts University
- Member of the Board for BIO Ventures for Global Health and the New England Healthcare Institute
|
| Dennis Purcell |
Director |
- Senior Managing Director of Aisling Capital LLC, a private equity firm that advises the Perseus-Soros Biopharmaceutical Fund, LP.
- Director of Auxilium Pharmaceuticals, Inc.
- B.S. in economics and accounting from the University of Delaware and an M.B.A. from Harvard University.
|
| Steven St. Peter, M.D. |
Director |
- Several positions at MPM Capital, a venture capital firm specializing in the life sciences industry, including General Partner since June 2005.
- Principal of Apax Partners, a private equity firm that invests in various industry sectors, including the healthcare industry.
- Senior Associate at the Carlyle Group, a private equity firm that invests in various industry sectors, including the healthcare industry.
- Director of PharmAthene, Inc., Helicos BioSciences Corporation and Omrix Biopharmaceuticals, Inc.
- B.A. in chemistry from the University of Kansas, an M.B.A. from the Wharton School of the University of Pennsylvania and an M.D. from Washington University.
- Board certified in internal medicine.
|
| Patrick Enright |
Director |
- Co-Founder and Managing Director, Longitude Capital
- Managing Director, Pequot Ventures
- Managing Member, Delta Opportunity Fund
- CFO & SVP Business Development positions at Valentis and Boehringer Mannheim Pharmaceuticals
- Member of the Board for Corcept Therapeutics (NASDAQ: CORT), Jazz Pharmaceuticals (NASDAQ: JAZZ) and multiple privately-held companies.
- B. S. in biological sciences from Stanford University and an M.B.A. from the Wharton School of Business at the University of Pennsylvania
|
| Craig A. Tooman |
Director |
- Executive Vice President, Finance and Chief Financial Officer of Enzon Pharmaceuticals, Inc., a biopharmaceutical company.
- Senior Vice President of Strategic Planning and Corporate Communications for ILEX Oncology, Inc., a biopharmaceutical company.
- Masters degree in finance from the University of Chicago.
|
| James Shannon, M.D. |
Director |
- Member of the Board of Directors of Cerimon Pharmaceuticals, Mannkind Corporation, Crucell, Endocyte Inc., Biotie Therapies, and Arch Therapeutics
- Head of Global Development for Novartis Pharma AG
- Head of Clinical Development & Medical Affairs for Novartis Pharma AG
- Head of R&D Integration Office for Novartis AG
- SVP and Chief Medical Officer for Sterling Winthrop
- MD - Queen's University Belfast
|
